A Story of Hope For Kids With Rare Disease
As we head into Thanksgiving, I wanted to share a story that highlights the promise and possibility that can emerge from a devastating diagnosis, and... Read More
Your Edge In Biotech.
About David Shaywitz
David Shaywitz, MD PhD is a contributing writer for Timmerman Report.
Focus: the transformational opportunities and implementation challenges presented by emerging technologies in healthcare, biomedical discovery, and biopharmaceutical development, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. Co-author (with Lisa Suennen): Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? (Hyperink Press, 2014).
Background: Drawing on two decades of biopharma experience, Dr. Shaywitz applies deep R&D expertise to guide and invest in the strategic adoption of emerging technologies to accelerate the discovery, development and delivery of impactful new therapies for patients.
Dr. Shaywitz’s career has centered on advancing pharmaceutical research by appreciating the transformative potential of nascent technologies while also recognizing the unique challenges of incorporating these technologies into complex biopharma environments. He has particular expertise in guiding promising technology and technology innovators through the complex scientific, cultural, and organizational landscape of biopharma.In addition to his writing for TR, Dr. Shaywitz is also a frequent speaker and writer on topics at the intersection of medicine, science, and innovation, and contributes book reviews regularly to the Wall Street Journal.
Dr. Shaywitz serves as a lecturer in the Department of Biomedical Informatics at Harvard Medical School, is an advisor to the MS/MBA Biotechnology Life Science Program at Harvard GSAS/HBS, and is an Adjunct Scholar at the American Enterprise Institute.
Latest Contributions
Coastal Culture Clash Around AI in Biotech
“Does the crowd understand? Is it East versus West Or man against man? Can any nation stand alone?” Burning Heart, by Survivor – Rocky IV... Read More
And Just Like That: What the Viral Adoption of a Clinical AI App Means for Pharma R&D
In 2011, we were experiencing the ascension of technologies like the cloud and the smartphone. Apps had become a thing: social network apps like Instagram... Read More
Yes We Can: My Response To Skeptical Readers
Two weeks ago, I wrote about how difficult it is for R&D leaders to “pick winners,” despite the enormous incentives to do so. I explained... Read More
Can We Pick Winners With Causal Human Biology? Vertex Makes the Case
Everybody reading this column knows that biopharma is a difficult business. Biology is unfathomably complicated and figuring out how to introduce something into the human... Read More
What If You Can’t Pick Winners in R&D?
Peter Thiel, the contrarian investor, had a favorite question for interviewees: “What important truth do few people agree with you on?” My answer: No one... Read More
Two New Books About Risk, Luck, and Skill Offer Insights For R&D Leaders
A central challenge of R&D, like many disciplines characterized by rare, outsized success, is how to think about risk, as well as the contributions of... Read More
AI in Pharma: Can We Get Beyond “Assent Without Belief” By Channeling Ethan Mollick?
The phrase “assent without belief” has been used to describe the concept of going along with the outward manifestations of an ideology without true conviction.... Read More